Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic.
作者信息
Ragavan Meera V, Legaspi Nichole, LaLanne Alyssa, Hong Julian C, Small Eric J, Borno Hala T
机构信息
Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco.
出版信息
JAMA Oncol. 2022 Dec 1;8(12):1849-1851. doi: 10.1001/jamaoncol.2022.4919.
Abstract
摘要
相似文献
1
Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic.
JAMA Oncol. 2022 Dec 1;8(12):1849-1851. doi: 10.1001/jamaoncol.2022.4919.
2
Effects of the COVID-19 Pandemic on Spontaneous Reporting: Global and National Time-series Analyses.
Clin Ther. 2021 Feb;43(2):360-368.e5. doi: 10.1016/j.clinthera.2020.12.008. Epub 2020 Dec 18.
3
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
4
Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?
Drug Saf. 2020 Mar;43(3):295-296. doi: 10.1007/s40264-019-00894-3.
5
Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity.
Oncologist. 2018 Jan;23(1):1. doi: 10.1634/theoncologist.2017-0437. Epub 2017 Nov 20.
6
Adverse event reporting in cancer clinical trial publications.
J Clin Oncol. 2014 Jan 10;32(2):83-9. doi: 10.1200/JCO.2013.52.2219. Epub 2013 Dec 9.
7
Supporting quality and patient safety in cancer clinical trials.
Clin J Oncol Nurs. 2011 Jun;15(3):263-5. doi: 10.1188/11.CJON.263-265.
8
How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
Drug Saf. 2021 Jan;44(1):1-5. doi: 10.1007/s40264-020-01018-y. Epub 2020 Nov 21.
9
Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system.
Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):707-715. doi: 10.1002/pds.5217. Epub 2021 Mar 17.
10
The COVID-19 pandemic and new clinical trial activations.
Trials. 2021 Apr 8;22(1):260. doi: 10.1186/s13063-021-05219-3.
引用本文的文献
1
Impact of the COVID-19 Pandemic on Cancer Clinical Trials: Alliance for Clinical Trials in Oncology Experience (Alliance A152022).
J Clin Trials. 2024;14(5). Epub 2024 Jul 25.
2
Patient Safety and Satisfaction With Fully Remote Management of Radiation Oncology Care.
JAMA Netw Open. 2024 Jun 3;7(6):e2416570. doi: 10.1001/jamanetworkopen.2024.16570.
3
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
Clin Cancer Res. 2024 Aug 1;30(15):3200-3210. doi: 10.1158/1078-0432.CCR-24-0400.
4
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
Dermatol Ther (Heidelb). 2024 Mar;14(3):729-743. doi: 10.1007/s13555-024-01122-2. Epub 2024 Mar 7.
5
The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.
Cancer Res Treat. 2024 Apr;56(2):422-429. doi: 10.4143/crt.2023.913. Epub 2023 Oct 23.
Zotero 插件